Objective-The goal of this study was to investigate the role of platelets in systemic and cardiac inflammatory responses and the development of postinfarct ventricular complications, as well as the efficacy of antiplatelet interventions. Methods and Results-Using a mouse myocardial infarction (MI) model, we determined platelet accumulation and severity of inflammation within the infarcted myocardium by immunohistochemistry and biochemical assays, analyzed peripheral blood platelet-leukocyte conjugation using flow cytometry, and tested antiplatelet interventions, including thienopyridines and platelet depletion. Platelets accumulated within the infarcted region early post-MI and colocalized with inflammatory cells. MI evoked early increase in circulating platelet-leukocyte conjugation mediated by P-selectin/P-selectin glycoprotein ligand-1. Antiplatelet interventions inhibited platelet-leukocyte conjugation in peripheral blood, inflammatory infiltration, content of matrix metalloproteinases or plasminogen activation, and expression of inflammatory mediators in the infarcted myocardium (all PϽ0.05) and lowered rupture incidence (PϽ0.01). Clopidogrel therapy alleviated the extent of chronic ventricular dilatation by serial echocardiography. Conclusion-Platelets play a pivotal role in promoting systemic and cardiac inflammatory responses post-MI. Platelets accumulate within the infarcted myocardium, contributing to regional inflammation, ventricular remodeling, and rupture. Antiplatelet therapy reduces the severity of inflammation and risk of post-MI complications, demonstrating a previously unrecognized protective action. (Arterioscler Thromb Vasc Biol. 2011;31:834-841.)
T he role of platelets in atherosclerotic lesions and acute coronary syndrome has been well documented. The proinflammatory actions of platelets have received increasing attention. 1, 2 Platelets contribute to inflammatory responses through release of inflammatory mediators and plateletleukocyte interactions by which platelets mediate leukocyte activation and infiltration into inflamed tissues. 1, 2 There are several reports of an elevated proportion of platelet-leukocyte aggregates tested ex vivo in blood samples from patients with acute coronary syndromes. [3] [4] [5] The current rationale for routine use of the platelet P2Y 12 receptor inhibitors thienopyridines (clopidogrel and prasugrel) is to prevent arterial thrombosis following coronary intervention. 6 Thienopyridine treatment is known to inhibit platelet-leukocyte interactions in the peripheral blood of patients with peripheral atherosclerotic vascular disease, coronary artery disease, or renal transplantation. 5, 6 Myocardial infarction (MI) evokes intense inflammatory responses both systemically and within the infarcted myocardium, with adverse consequences. 7 The potential contribution of platelets to postinfarct cardiac inflammation remains unexplored. Relevant to this is the question of whether thienopyridines exert cardiac protection through inhibition of platelet's inflammatory action in the infarcted myocardium, independent of vascular thrombosis.
Ventricular wall rupture is a fatal complication of acute MI, with a death rate of 70% to 90%. 8, 9 Recent experimental studies, including ours, have provided strong evidence that wall rupture is the consequence of severe regional inflammation and elevation of proteinases, particularly matrix metalloproteinases (MMPs) and plasmin, with subsequent damage to extracellular matrix proteins and reduction in tissue tensile strength. 10 -14 Thus, interventions such as MMP inhibitors and gene disruption of MMP-9, MMP-2, or urokinase plasmino-gen activator (uPA) reduced rupture incidence. 10, 12, 13 More severe inflammation, with a higher level of MMP-9 or C-reactive protein, was also reported in infarcted patients who had rupture compared with those without rupture. [15] [16] [17] [18] The mouse is the only laboratory species that develops rupture after acute MI. The mouse model of rupture simulates many features seen in human ventricular rupture and also displays overt infarct expansion in the acute phase and ventricular remodeling chronically. 10 -12 Here, we report findings suggesting a pivotal role for platelets in systemic and myocardial inflammation and wall rupture pathogenesis following acute MI that were effectively inhibited by treatment with thienopyridines. These findings reveal additional efficacy of antiplatelet interventions in the setting of acute MI.
Methods
A detailed description is presented in the Supplemental Materials, available online at http://atvb.ahajournals.org.
Animals and Surgery
All experimental procedures were approved by a local animal ethics committee. Male C57Bl/6 mice were operated on for permanent occlusion of the left coronary artery or sham operation. 11 To generate tissues for assays, animals were killed at day 2 or 3 after MI, and infarct and noninfarct portions of the left ventricle (LV) were separated. Animals allocated to the rupture incidence were closely monitored for 7 days; autopsy was performed once animals were found dead to determine the reason of death, and infarct size was determined. 11
Treatment With Test Agents
Animals were randomly assigned to different groups after surgery, and all treatment started 2 hours after MI and lasted for 3 days. Clopidogrel was given by daily gavage at 2 different doses (50/15/15 and 15/5/5 mg/kg). Prasugrel was tested at 5/5/5 mg/kg. CD41 antibody (BD Biosciences) or control IgG antibody was used at 0.5 mg/kg IP for 3 days to induce thrombocytopenia. Inhibition of platelet activity by the interventions was assessed by tail bleeding test.
To investigate the role of P-selectin glycoprotein ligand-1 (PSGL-1) in platelet-leukocyte conjugation, 2 hours after MI, mice were treated with PSGL-1 blocking antibody (BD Pharmingen, 2 mg/kg IP). Blood samples were collected 24 hours after MI.
Immunohistochemistry and Carstair Stain
Mouse hearts were harvested at different time points after MI, and paraffin or cryostat sections prepared for Carstair stain or immunohistochemistry, respectively. For platelet detection, immunohistochemistry was performed using anti-mouse glycoprotein IIb (CD41) monoclonal antibody, and images were analyzed digitally using ImagePro software. The average of percentages per fields was used. For quantitation of inflammatory cell density, frozen sections were stained with rat anti-mouse CD45 antibody, and nuclei were stained using 4Ј,6-diamidino-2-phenylindole. The number of inflammatory cells was counted.
Flow Cytometry for Platelet-Leukocyte Conjugation and P-Selectin ؉ Platelets
Blood samples were collected and processed within 30 minutes at room temperature. After lysing red blood cells, leukocytes were labeled with PerCP-conjugated anti-mouse CD45 and platelets with fluorescein isothiocyanate-conjugated anti-mouse CD62P (Pselectin). Leukocytes (20 000/sample) were analyzed with a Becton-Dickinson FACSCalibur flow cytometer and FlowJo software.
Washed platelets (10 6 cells) were labeled with phycoerythrinconjugated anti-mouse CD41, and activated platelets were labeled with fluorescein isothiocyanate-conjugated anti-mouse CD62P; 10 5 platelets per sample were analyzed with the flow cytometer.
Western Blotting
Content of CD41 or plasminogen activator inhibitor-1 (PAI-1) in sham-operated and infarct cardiac tissue (day 3) was determined by Western blot.
Quantitative Real-Time Polymerase Chain Reaction, Gelatin Zymography, and ELISA
Infarct and noninfarct portions of the LV were collected from infarct mice for gene expression of inflammatory mediators by real-time polymerase chain reaction or for gelatin zymography and ELISA.
Plasminogen Activation Assay
Amidolytic assays with modifications were performed in lysates of heart tissues from sham-operated and infarct mice for detection of plasminogen activation parameters. Activities of urokinase plasminogen activator (uPa) or tissue-type PA (tPA) were determined using their respective inhibitors.
Echocardiography
Echocardiography was performed as described previously. 10 Shortaxis view of the LV was obtained. Images were analyzed for LV dimensions and cross-sectional areas at end-diastole.
Statistics
Results are expressed as either meanϮSEM or percentages. Using GraphPad Instat software, results were analyzed by ANOVA followed by Newman-Keuls multiple comparison test or Fisher's exact test, respectively. Echocardiographic data were analyzed by 2-way ANOVA for repeated measures. PϽ0.05 was considered statistically significant.
Results

Platelet Accumulation Within the Infarcted Myocardium
Time-dependent accumulation of platelets within the infarcted myocardium was estimated by immunohistochemistry using CD41 antibody at 3, 6, 12, 24, and 72 hours after MI or by Carstair's stain at 24 and 72 hours (nϭ4 to 5 at each time point per staining). We observed that platelets accumulated in the interstitium of the infarcted region as early as 6 hours after MI and becoming increasingly prominent thereafter ( Figure  1A to 1D). At 72 hours after MI, platelet accumulation was widespread within the infarcted myocardium. Colocalization of platelets with dense inflammatory cells was also common within the infarcted region after 6 hours ( Figure 1B and 1C), with platelet particles visible under high magnification (Figure 1B) . Although aggregates of platelets and leukocytes were visible in microvessels, positive platelet stain was largely extravascular in location. Both quantitative histology and Western blot showed substantial platelet accumulation in the infarcted myocardium ( Figure 1D and 1E).
Antiplatelet Therapy Suppressed Inflammatory Responses in the Infarcted Myocardium
We then examined effects of thienopyridines or platelet depletion in the MI model. These therapies significantly prolonged tail bleeding time (Figure 2A ). Whereas the bleeding time appeared similarly prolonged in mice receiving
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clopidogrel at high or low dose, the amount of bleeding was greater in the high-dose group (0.8 to 1.1 mL/20 minutes) than in the low-dose group (0.2 to 0.4 mL/20 minutes). The severity of myocardial inflammation was estimated by quantification of (1) density of CD45 ϩ cells by immunohistochemistry (nϭ7 to 8/group), (2) content and activity of MMP-2 and MMP-9 by gelatin zymography (nϭ4 to 5/group), (3) gene expression of inflammatory mediators by quantitative real-time polymerase chain reaction (nϭ6 to 7/group), and (4) assay of selected cytokines by ELISA. Measurements were performed using infarcted and noninfarcted LV tissues collected at day 2 (for gene expression) or day 3 (for zymography, immunohistochemistry, or ELISA). Immunohistochemistry revealed that treatment with clopidogrel, prasugrel, or CD41 antibody significantly and similarly reduced the density of leukocytes within the infarcted area by 20% to 30% ( Figure 2B and 2C ). Furthermore, quantitative real-time polymerase chain reaction showed a significant suppression by clopidogrel therapy of elevated expression of MMP-9, MMP-13, interleukin-1␤, and tumor necrosis factor-␣, although other selected genes were not altered by this treatment (Supplemental Figure I) . Previous studies have shown that increased levels of MMP-2 and MMP-9 are critical for rupture development. 10 -13 Gelatin zymography revealed lower levels of both MMP-9 and MMP-2 in the infarcted myocardium of mice treated with clopidogrel (Supplemental Figure IIA) . Clopidogrel therapy also significantly reduced protein content of tumor necrosis factor-␣ and interleukin-1␤ by ELISA (Supplemental Figure  IIB ) and the amount of platelet accumulation in the infarcted myocardium by quantitative histology ( Figure 1D ).
Plasminogen Activators and Effect of Antiplatelet Interventions
The plasminogen/PA system is known to contribute to ventricular rupture and remodeling postinfarction. 12, 14 Using the amidolytic assay on mouse heart protein lysates, we found that uPA was the predominant PA in the mouse heart and that MI was associated with increased uPA but decreased tPA activity relative to sham values ( Figure 3A and 3B). Clopidogrel significantly prevented the MI-induced increase in uPA activity, and platelet depletion tended to lower it. uPA activity is endogenously suppressed by PAI-1. Western blot revealed that the tissue content of PAI-1 was not significantly altered either by MI or by antiplatelet interventions (Figure 3C ).
Acute MI Evoked Platelet-Leukocyte Conjugation and the Mechanism Involved
Using flow cytometry, we measured platelet-leukocyte conjugation in peripheral blood from mice with sham surgery or MI (nϭ5 to 12/group). Acute MI led to a clear increase over the baseline value in platelet-monocyte conjugation as early as 6 hours, which progressively increased up to 72 hours after MI ( Figure 4A and 4B). Platelet conjugation with granulocytes and lymphocytes was also significantly elevated by 72 hours (Supplemental Figure III, Figure 4B ). Platelet aggregation was also detected microscopically in peripheral blood mononuclear cells from mice following MI ( Figure 4C ).
We then explored the mechanism underlying the postinfarct platelet-leukocyte interaction, focusing on P-selectin/ PSGL-1. Following MI, the proportion of P-selectin expressing platelets increased significantly at 24 and 72 hours, indicating platelet activation ( Figure 5A ). PSGL-1 blocking antibody given 2 hours after surgery abolished MI-stimulated platelet-monocyte conjugation ( Figure 5B ).
Effects of Antiplatelet Therapy in the MI Model
Effect of clopidogrel (50/15/15 mg/kg) therapy on flow cytometry-derived parameters were analyzed in blood sam-ples collected at 24 and 72 hours after MI. Clopidogrel therapy inhibited MI-induced increase in proportion of P-selectin expressing platelets ( Figure 5A ) and abolished platelet-monocyte conjugation without influencing the basal value ( Figure 6 ). Platelet depletion prevented not only MIinduced but also the baseline conjugation measured at 72 hours post-MI ( Figure 6 ).
Postinfarct ventricular rupture and remodeling are important clinical events and closely related to cardiac inflammation. 7,10 -17 We further evaluated the efficacy of antiplatelet interventions on rupture incidence and degree of ventricular remodeling. A total of 117 mice with MI were monitored up to 7 days. In an untreated group, 46% of animals (24 of 52) died of rupture during 3 to 6 days. Treatment with clopidogrel at 2 dosages or with CD41 antibody for 3 days after MI similarly reduced rupture incidence (PϽ0.01 versus untreated group, Figure 7A ). Infarct size was comparable among the groups ( Figure 7A ). Surviving mice (nϭ15) in the clopidogrel-treated group were further monitored up to 14 days, but no rupture occurred during this extended week, confirming that rupture was prevented, rather than delayed.
We further examined the potential long-term effect of clopidogrel therapy in infarct mice without and with 3-day clopidogrel treatment (50/15/15 mg/kg). Serial echocardiography was performed before and during the 1 to 4 weeks after MI. Both groups had comparable infarct size (treated 38.2Ϯ1.2%; untreated: 39.9Ϯ1.0%). Echocardiography showed significant LV enlargement post-MI; measured independently by LV dimension or cross-sectional area, LV dilatation was significantly less in the clopidogrel-treated group ( Figure 7B ). This beneficial effect was already detectable at week 1 post-MI and was maintained throughout the 4-week period. There was no significant difference in LV contractile function between the 2 groups (data not shown).
Discussion
We have made several novel findings in this study. (1) Platelets are among the first wave of inflammatory cells accumulating within the infarcted myocardium colocalizing with infiltrated leukocytes. (2) MI promotes conjugation of circulating platelets and leukocytes, which is largely medi- ated by P-selectin/PSGL-1. (3) Antiplatelet therapy significantly suppressed the extent of regional cardiac inflammation, evidenced by reduced inflammatory cell density, MMP abundance/activity, and expression of key inflammatory markers, together with platelet-leukocyte conjugation in peripheral blood, effects mostly likely due to inhibition of platelet-mediated leukocyte activation occurring at peripheral blood and tissue levels and subsequent infiltration into infarct tissues. (4) Clopidogrel therapy prevented MI-induced increase in uPA. (5) Clopidogrel therapy suppressed the incidence of ventricular rupture in the acute phase and mitigated ventricular remodeling in chronic phase of MI, complications closely related to regional inflammation. 10 -14 These findings provide proof-of-concept evidence for cardiac protection of antiplatelet therapy in addition to its antithrombotic action in acute MI.
Intravascular thrombosis has been the focus of interest in acute coronary syndromes and forms the rationale for routine thienopyridine treatment. Clinical trials have documented broad benefits, including survival, when administered at the time of presentation of symptoms. 19 -21 Experimental studies have shown that ischemia-reperfusion triggers platelet aggregation within coronary vessels that can be inhibited by interventions such as deletion of P-selectin or the intracellular adhesion molecule-1gene. [22] [23] [24] In our study, platelet accumulation in the mouse infarcted myocardium is unique in its largely extravascular location, early presence, and close association with infiltrated inflammatory cells. How do circulating platelets enter into the interstitial space of the infarcted myocardium? One mechanism indicated by our findings involves platelets aggregating with circulating leukocytes and then piggy-backing into the infarcted myocardium. Platelet-leukocyte conjugation in peripheral blood and colocalization of platelets and inflammatory cells within the tissue occur as early as 6 hours after MI. A higher level of platelet-monocyte conjugation detected in peripheral blood soon after MI is in keeping with the fact that majority of infiltrates in the infarcted myocardium are monocytes or macrophages during the acute phase. 10 Considering the dynamic nature of platelet-leukocyte aggregation and leukocytes infiltrating into the infarcted region, our quantitation of P-selectin-expressing platelets and plateletleukocyte aggregates likely underestimates the degree of systematic inflammatory responses. Platelets may also enter into the infarct myocardium, with intramural bleeding occurring in the mouse or human patients with MI, 11, 25 likely because of vessel damage or increased vascular permeability. 11 Thus, platelets might leave the blood stream through injured microvessels and, once in the infarcted myocardium, be tethered to exposed matrix materials or injured cells through specific ligands or receptors. 1 We recently observed that clopidogrel therapy had no effect on the extent of intramyocardial hemorrhage. 26 Higher levels of ex vivo platelet-leukocyte aggregates have been reported in patients with acute coronary syndrome, [3] [4] [5] and clopidogrel treatment is known to inhibit plateletleukocyte conjugation stimulated ex vivo in patients with peripheral atherosclerotic vascular disease or coronary artery disease. 5, 6 There has been no report on such efficacy in vivo or its relation to inflammation in the infarcted myocardium.
Here, we observed simultaneous suppression by clopidogrel therapy of platelet-leukocyte conjugation in peripheral blood and the severity of inflammation in the infarcted myocardium, in which platelets contribute significantly to both systemic and regional inflammatory responses. P2Y 12 expression is largely limited to platelets. 6 The similarity of antiinflammatory efficacy achieved by clopidogrel, prasugrel, or platelet depletion strongly suggests that platelet inhibition by thienopyridines is via blocking P2Y 12 . 1, 2 Platelets function as inflammatory cells through numerous membrane molecules and granular release of inflammatory mediators. 1, 2, 27 Platelets promote inflammatory responses by 2 fundamental mechanisms: granular release of inflammatory mediators, such as serotonin, histamine, chemokines, cytokines, and MMPs 2,27 ; and platelet-leukocyte interactions contributing to leukocyte activation and recruitment to inflamed tissues. 1, 2 On platelet activation and degranulation, P-selectin rapidly translocates from ␣-granule to platelet surface. 1,2 P-selectin can then bind to PSGL-1 on the surface of leukocytes, forming aggregates. We showed that blockade of PSGL-1 prevented MI-stimulated platelet-monocyte aggregation in circulating blood. Interestingly, treatment with clopi- dogrel inhibited the proportion of P-selectin-expressing platelets in addition to potent inhibition of platelet-leukocyte aggregation and myocardial inflammation. These findings support the view that P2Y 12 plays a fundamental role in postinfarct platelet activation and platelet-leukocyte interactions, contributing to cardiac inflammation.
Considering that inflammatory cell-derived MMPs and subsequent breakdown of collagen fibers are the central mechanism of postinfarct ventricular rupture, 10 -14 the proinflammatory nature of activated platelets is expected to contribute to the development of ventricular rupture. Similar to the inhibition of rupture events by gene disruption of MMP-9 or MMP-2 12, 13 or by treatment with MMP inhibitors, 10 here we showed, for the first time, inhibition by antiplatelet interventions on the severity of inflammation and wall rupture following MI. Our findings indicate that plateletleukocyte aggregates, particularly mononuclear cells, play a critical role in initiating early inflammatory responses post-MI.
In addition to activation of MMPs, plasminogen activation also promotes post-MI ventricular rupture and healing. 12, 14 Whereas MI-induced wall rupture is abolished in uPA (but not tPA)-deficient mice, PAI-1 disruption exacerbates post-MI wall rupture. 12, 14 We observed for the first time that antiplatelet therapy suppressed uPA activity in the infarcted myocardium without change in PAI-1 abundance. Thus, antiplatelet interventions profoundly inhibit an array of inflammatory responses following MI, including the plasmin/ MMP proteinase system.
Although the current incidence is low (1% to 3%), ventricular rupture post-MI remains a lethal complication. 8, 9, 28 Clinical information is limited regarding thienopyridine therapy and risk of postinfarct rupture. Of several large-scale clinical trials on clopidogrel, COMMIT 20 and CLARITY 21 are the only ones on patients with acute MI. Although both trials showed significant benefits by thienopyridine treatment, including several primary end points, there was no significant change in the incidence of rupture in COMMIT trial (0.8% versus 0.9%) 20 and no report of rupture incidence in CLAR-ITY trial, 21 although the former was limited by the lack of a loading dose of clopidogrel. In a large registry (GRACE), it was found that the use of thienopyridine was significantly lower in patients who developed rupture post-MI compared with rupture-free patients. 28 Using the mouse model, we demonstrated a potent inhibition by antiplatelet interventions on ventricular rupture, with its onset closely related to infarct expansion. 11 We also observed alleviated chronic ventricular dilatation by clopidogrel therapy, an efficacy detectable at day 7 post-MI, suggesting inhibition of acute infarct expansion as the explanation for this long-term benefit. Importantly, these benefits were achieved by administering antiplatelet agents within the first 3 days after MI. Although these findings were made on the murine MI model, their clinical relevance is indicated by studies showing severe inflammatory cell infiltration and intramyocardial bleeding in human hearts, detected by histopathologic or clinical imaging means, 17, 18, 25 and an increased platelet-leukocyte aggregates in patients with acute coronary events. 4, 5, 29, 30 Additional clinical trials are warranted to test whether these findings might pertain to patients with acute MI.
Earlier studies using cardiac ischemia/reperfusion models have shown that because of formation of microthrombi and release of vasoconstrictors, such as thromboxanes, platelets exacerbate cardiac injury and dysfunction with reduced coronary blood flow. 24, 30 Recent studies revealed increased infarct size following ischemia/reperfusion due to an activated platelet activity. 24, 30 To limit the influence of vascular thrombosis, we adopted a permanent coronary artery occlusion model, although microthrombi were still visible within the infarct myocardium. Furthermore, the efficacy of thienopyridine was observed, with comparable infarct size between treated and untreated groups. The dosages of clopidogrel tested in the current study would be expected to inhibit platelet activity by 50% to 90%. Clinically, a steady-state effect of clopidogrel is 50% to 60% inhibition of ADPinduced platelet activation. 31 However, 20% to 40% of patients display clopidogrel resistance, for a variety of reasons. 32 It would be important to examine whether patients who respond poorly to antiplatelet drugs might have more severe inflammation and higher risk of ventricular rupture post-MI. Furthermore, our findings of increased plateletleukocyte conjugation in the peripheral blood of infarcted mice and the effect of clopidogrel therapy strongly indicate that this measure is a useful clinical biomarker.
In conclusion, we have shown that increased plateletleukocyte aggregation and regional accumulation and activation of platelets contribute to myocardial inflammation and wall rupture in the mouse MI model. These changes are inhibited by antiplatelet interventions, indicating direct cardiac protection via attenuation of inflammatory responses. Although our findings were made in the murine MI model, they are in keeping with the current consensus of platelets being a class of inflammatory cells and highlight the previously unrecognized efficacy of antiplatelet therapy in the setting of acute MI.
Sources of Funding
This study was funded by grants from the National Health and Medical Research Council of Australia (NHMRC). Dr Jackson is an Australian Fellow and Drs Medcalf, Dart, and Du are NHMRC Fellows.
